Researchers fine-tune blood thinner dosing for chinese heart patients
NCT ID NCT05320627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the blood thinner edoxaban behaves in 150 Chinese adults with non-valvular atrial fibrillation (an irregular heartbeat). The goal was to see if current dosing models fit Chinese patients and to create a more personalized dosing plan to improve effectiveness and reduce side effects. Participants gave blood samples to measure drug levels and clotting activity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-VALVULAR ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100037, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common blood thinner shield your brain from dementia?
- Heart procedure showdown: which imaging method is safer?
- Heart procedure may stop bladder bleeding without blood thinners
- New heart device aims to cut stroke risk without lifelong blood thinners
- New study sets standard blood levels for stroke prevention drugs in chinese patients
- New heart plug could free AF patients from lifelong blood thinners